Posts Tagged ‘drug compounding’

In a dim corner of drug regulation, we’re on the cusp of “a hot peptide summer.” That’s the word from Dean Stattmann at GQ. Writing as a men’s health and lifestyle reporter (not a health professional) he explains: “In late February, health secretary Robert F. Kennedy Jr. joined Joe Rogan on his podcast, revealing that […]

The twisted relationship of Hims and Novo Nordisk took another sharp turn this week. Novo withdrew its patent infringement lawsuit against Hims & Hers – barely a month after filing the suit. The company is now crowing about selling its Ozempic and Wegovy products through “leading telehealth providers” like Hims. But they “reserve the right […]

Recent news from Hims & Hers adds to our discomforting thought that compounded GLP-1s have become little more than a ploy to grab quick money from vulnerable consumers. Thursday, the company announced they are launching a compounded semaglutide tablet to compete with Wegovy. Reporting from Reuters suggests this announcement aimed to spark gains in their […]

The short supply, high prices, and despicable insurance restrictions for advanced obesity medicines have created many problems. For example, compounding of these medicines has been and continues to be controversial – for good reasons. Now, FDA is recognizing one of the most pernicious threats to emerge from this situation – sketchy sellers of “research” peptides. […]

The last legitimate path for GLP-1 compounding closes on May 22 and consumer protection advocates are worried about rabbit holes opening up to exploit the desperation of some patients. Yesterday, the National Consumer League (NCL) released survey results to suggest a great deal of confusion and misinformation about off-brand versions of GLP-1 medicines. Perhaps more […]

In the U.S., we are at a critical point for the sourcing obesity medicines. March 19 was the last day that FDA would tolerate large scale compounding of tirzepatide on account of the now resolved shortage of that drug. The same milestone for semaglutide is coming up on May 22. Some people are not happy. […]

Was the multi-million dollar spend by Hims & Hers on a Super Bowl ad the last gasp of a doomed business? Or was it a clever play for regulatory latitude that could keep them going?  Conventional wisdom suggests that GLP-1 compounders should be nearing the end of their rope. But some political observers think they […]

A telehealth business has a slick, defiant commercial for their compounded weight loss medication ready to run during the Super Bowl tomorrow. More than a few doctors are definitely not amused. They are not the only ones. Two senators have written to the acting head of the FDA to say that caution and fair balance […]

It’s too dangerous, say some. In fact, quite sincerely, smart physicians have told us that the widespread use of compounded semaglutide represents a public health crisis. Others have told us that, yes, there are risks. But because of drug pricing and health insurance practices, it is the only option for many patients and they have […]

This year is rapidly winding down and already, our gaze is shifting toward expectations for the coming year. So before that shift is complete and we start making predictions for 2025, let’s check the scorecard for the expectations we had for 2024. A year ago, we put forward predictions of five hot topics for the […]